ANIP FY 2023 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

FY 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$487M+53.9% YoY

Gross Profit

$305M62.7% margin

Operating Income

$47M9.6% margin

Net Income

$19M3.9% margin

EPS (Diluted)

$0.94

Cash Flow

Operating Cash Flow

$119M

Free Cash Flow

$100M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$904M

Total Liabilities

$447M

Stockholders' Equity

$458M

Cash & Equivalents

$221M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$487M	$316M	+53.9%
Gross Profit	$305M	$178M	+71.9%
Operating Income	$47M	-$35M	+233.1%
Net Income	$19M	-$48M	+139.2%